<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059617</url>
  </required_header>
  <id_info>
    <org_study_id>113483</org_study_id>
    <nct_id>NCT01059617</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults</brief_title>
  <official_title>A Study to Evaluate Immune Responses Following A/California/7/2009 (H1N1)V-like Virus Vaccination Given 4 Months Following Seasonal Influenza Vaccination in Adults 19 to 40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to characterize the safety and immunogenicity of a' pandemic
      influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never
      received influenza vaccination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164 to Day 122).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28 These data were not available. This summary will be updated when the results become available.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164 to Day 122).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
    <safety_issue>No</safety_issue>
    <description>VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28 These data were not available. This summary will be updated when the results become available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>At Day 122 and Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>At Day 122 and Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>For the entire study period up to Day 507</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>At Day 0 and Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>At Day 0 and Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>For the entire study period up to Day 507</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</measure>
    <time_frame>For the entire study period up to Day 507</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</measure>
    <time_frame>During the entire study period (up to Day 507).</time_frame>
    <safety_issue>No</safety_issue>
    <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</measure>
    <time_frame>During the entire study period (up to Day 507).</time_frame>
    <safety_issue>No</safety_issue>
    <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs.</measure>
    <time_frame>Up to 21-day (Days 0-20) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AEs were collected after the administration of the Flulaval vaccine or the placebo dose.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs.</measure>
    <time_frame>Within 84 days following first dose or 63 days following second dose of vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AEs were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (up to Day 507).</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Case Descriptions for Subjects Experiencing Reverse Transcription-polymerase Chain Reaction (RT-PCR) and Culture-confirmed Influenza.</measure>
    <time_frame>During the entire study period (up to Day 507).</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>Up to Day 234</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination. Missing values will be added once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</measure>
    <time_frame>Within Days 0-233</time_frame>
    <safety_issue>No</safety_issue>
    <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</measure>
    <time_frame>Within Days 0-233</time_frame>
    <safety_issue>No</safety_issue>
    <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms.</measure>
    <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Missing values will be added once they become available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</measure>
    <time_frame>On Days 0, 21, 122 and 164</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</measure>
    <time_frame>On Days 0, 21, 122 and 164</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatise (AP), creatinine (CREA), blood urea nitrogen (BUN) and bilirubin (BIL) (total (T) and direct (D)).
For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</measure>
    <time_frame>At Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</measure>
    <time_frame>At Day 304</time_frame>
    <safety_issue>No</safety_issue>
    <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), creatinine (CREA), blood urea nitrogen (BUN), and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</measure>
    <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</measure>
    <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Flulaval/Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flulaval/Unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' FluLaval®</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Flulaval/Arepanrix Group</arm_group_label>
    <arm_group_label>Flulaval/Unadjuvanted Arepanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo/Arepanrix Group</arm_group_label>
    <arm_group_label>Placebo/Unadjuvanted Arepanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A</intervention_name>
    <description>Intramuscular injections</description>
    <arm_group_label>Placebo/Arepanrix Group</arm_group_label>
    <arm_group_label>Flulaval/Arepanrix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A</intervention_name>
    <description>Intramuscular injections</description>
    <arm_group_label>Flulaval/Unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_label>Placebo/Unadjuvanted Arepanrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol (e.g., completion of the diary cards, return for follow-up visits).

          -  Written informed consent obtained from the subject.

          -  Male or female adults, 19-40 years of age at the time of the first vaccination.

          -  Body weight of at least 110 pounds (49.9 kg).

          -  Safety laboratory tests results within the parameters specified by protocol.

          -  Satisfactory baseline medical assessment by physical examination (stable health
             status with no exclusionary conditions). Stable health status is defined as the
             absence of a health event satisfying the definition of a serious adverse event, or a
             change in an ongoing drug therapy due to therapeutic failure or symptoms of drug
             toxicity, within one month prior to enrollment.

          -  Comprehension of the study requirements, ability to comprehend and comply with
             procedures for collection of safety data, expressed availability for the required
             study period, and ability and willingness to attend scheduled visits as documented by
             signature on the informed consent document.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
             device (i.e., a common-use phone serving multiple rooms or apartments).

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Non-childbearing potential is defined as current tubal ligation, hysterectomy,
             ovariectomy, or post-menopause.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  has practiced adequate contraception for 30 days prior to vaccination, and

          -  has a negative pregnancy test on the day of vaccination, and

          -  has agreed to continue adequate contraception during the entire treatment period and
             for 2 months after completion of the vaccination series

        Exclusion Criteria:

          -  Previous vaccination with an A/California/7/2009 (H1N1)v-like virus vaccine

          -  A medical history of physician-confirmed infection with an A/California/7/2009
             (H1N1)v-like virus.

          -  Prior receipt at any time of any seasonal influenza vaccine.

          -  Planned administration of any vaccine not foreseen by the study protocol (including
             any influenza vaccine other than the study vaccine) between Days 0 and the Day 164
             phlebotomy.

          -  Administration of any licensed vaccine within 30 days before the first study vaccine
             dose.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during the study period.

          -  Receipt of systemic glucocorticoids (e.g., prednisone ≥ 0.5 mg/kg/day, or ≥ 10 mg/day
             [whichever is less] for more than 14 consecutive days) within one month prior to
             study enrolment, or any other cytotoxic or immunosuppressive drug within six months
             of study enrolment. Topical, intra-articularly injected, or inhaled glucocorticoids,
             topical calcineurin inhibitors or imiquimod are allowed.

          -  Receipt of any immunoglobulins and/or any blood products within 9 months of study
             enrolment or planned administration of any of these products during the study period.

          -  Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
             which, even if stable, are deemed by the investigator to render the potential subject
             unable/unlikely to provide accurate safety reports.

          -  History of anemia.

          -  Presence of a temperature ≥ 38.0ºC (≥100.4ºF), (oral temperature assessment
             preferred), or acute symptoms greater than &quot;mild&quot; severity on the scheduled date of
             first vaccination

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination. (No laboratory testing is required.)

          -  Any significant disorder of coagulation or treatment with warfarin derivatives or
             heparin. Persons receiving individual doses of low molecular weight heparin outside
             of 24 hours prior to vaccination are eligible. Persons receiving prophylactic
             antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a
             clinically-apparent bleeding tendency, are eligible.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome within
             six weeks of receipt of any vaccine.

          -  Any known or suspected allergy to any constituent of influenza vaccines (including
             egg proteins or mercurial preservatives); a history of anaphylactic-type reaction to
             consumption of eggs; or a history of severe adverse reaction to any vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-HCG) test
             result prior to first vaccination.

          -  Lactating or nursing women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>July 12, 2012</lastchanged_date>
  <firstreceived_date>January 28, 2010</firstreceived_date>
  <firstreceived_results_date>January 31, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pandemic</keyword>
  <keyword>GSK Bio's influenza vaccine GSK2340274A</keyword>
  <keyword>H1N1</keyword>
  <keyword>Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flulaval/Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="P2">
          <title>Flulaval/Unadjuvanted Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="P4">
          <title>Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flulaval/Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="B2">
          <title>Flulaval/Unadjuvanted Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="B3">
          <title>Placebo/Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="B4">
          <title>Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="33"/>
                <measurement group_id="B4" value="33"/>
                <measurement group_id="B5" value="133"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.6" spread="6.44"/>
                <measurement group_id="B2" value="29.0" spread="7.05"/>
                <measurement group_id="B3" value="28.6" spread="6.17"/>
                <measurement group_id="B4" value="29.8" spread="7.24"/>
                <measurement group_id="B5" value="29.3" spread="6.73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="21"/>
                <measurement group_id="B5" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="12"/>
                <measurement group_id="B5" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164 to Day 122).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
            <units>Fold</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40.3" lower_limit="22.9" upper_limit="71.2"/>
                  <measurement group_id="O2" value="20.8" lower_limit="12.5" upper_limit="34.6"/>
                  <measurement group_id="O3" value="57.4" lower_limit="31.6" upper_limit="104.2"/>
                  <measurement group_id="O4" value="25.8" lower_limit="15.9" upper_limit="41.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="650.7" lower_limit="485.5" upper_limit="872.1"/>
                  <measurement group_id="O2" value="259.4" lower_limit="186.4" upper_limit="361.0"/>
                  <measurement group_id="O3" value="799.0" lower_limit="630.5" upper_limit="1012.4"/>
                  <measurement group_id="O4" value="332.7" lower_limit="222.0" upper_limit="498.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28 These data were not available. This summary will be updated when the results become available.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Seroconversion rate (SCR) was defined as the number of subjects who have either a pre-vaccination reciprocal HI titer &lt; 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Seroprotection rate (SPR) was defined as the number of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164 to Day 122).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Geometric mean fold-rise (GMFR), or seronversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.</description>
            <units>Fold</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.5" lower_limit="4.8" upper_limit="11.8"/>
                  <measurement group_id="O2" value="4.7" lower_limit="3.2" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.6" lower_limit="2.0" upper_limit="3.3"/>
                  <measurement group_id="O4" value="1.9" lower_limit="1.5" upper_limit="2.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="144.9" lower_limit="97.2" upper_limit="216.1"/>
                  <measurement group_id="O2" value="123.1" lower_limit="87.1" upper_limit="174.0"/>
                  <measurement group_id="O3" value="49.2" lower_limit="33.9" upper_limit="71.2"/>
                  <measurement group_id="O4" value="35.2" lower_limit="25.7" upper_limit="48.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>VRR for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0. The cut-off value for microneutralization titers is 1:28 These data were not available. This summary will be updated when the results become available.</description>
        <time_frame>21 days following the second dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccines (At Day 164).</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>At Day 122 and Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;=1:10 Flu A/CAL/7/09 H1N1 Day 122 (N=21;32;21;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;=1:10 Flu A/CAL/7/09 H1N1 Day 304 (N=21;32;21;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>At Day 122 and Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 122</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.1" lower_limit="8.9" upper_limit="29.3"/>
                  <measurement group_id="O2" value="12.8" lower_limit="7.8" upper_limit="21.0"/>
                  <measurement group_id="O3" value="15.6" lower_limit="8.2" upper_limit="29.5"/>
                  <measurement group_id="O4" value="12.9" lower_limit="8.1" upper_limit="20.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 304</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="157.4" lower_limit="98.2" upper_limit="252.2"/>
                  <measurement group_id="O2" value="100.3" lower_limit="68.0" upper_limit="148.2"/>
                  <measurement group_id="O3" value="289.9" lower_limit="188.2" upper_limit="446.6"/>
                  <measurement group_id="O4" value="116.0" lower_limit="72.7" upper_limit="185.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <time_frame>For the entire study period up to Day 507</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>At Day 0 and Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;=1:10 Flu A/BRI/59/07 H1N1 Day 0 (N=21;32;21;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;=1:10 Flu A/BRI/59/07 H1N1 Day 304 (N=21;32;21;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>At Day 0 and Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.3" lower_limit="13.2" upper_limit="28.2"/>
                  <measurement group_id="O2" value="25.6" lower_limit="17.2" upper_limit="37.9"/>
                  <measurement group_id="O3" value="21.6" lower_limit="15.4" upper_limit="30.4"/>
                  <measurement group_id="O4" value="18.2" lower_limit="12.4" upper_limit="26.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 Day 304</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="129.0" lower_limit="89.8" upper_limit="185.2"/>
                  <measurement group_id="O2" value="114.4" lower_limit="80.0" upper_limit="163.4"/>
                  <measurement group_id="O3" value="48.0" lower_limit="35.5" upper_limit="64.9"/>
                  <measurement group_id="O4" value="37.0" lower_limit="25.5" upper_limit="53.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <time_frame>For the entire study period up to Day 507</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</title>
        <time_frame>For the entire study period up to Day 507</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</title>
        <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period (up to Day 507).</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</title>
            <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any pIMDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related pIMDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</title>
        <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period (up to Day 507).</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</title>
            <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any MAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related MAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs.</title>
        <description>Unsolicited AEs were collected after the administration of the Flulaval vaccine or the placebo dose.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Up to 21-day (Days 0-20) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="67"/>
                  <measurement group_id="O6" value="66"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited AEs.</title>
            <description>Unsolicited AEs were collected after the administration of the Flulaval vaccine or the placebo dose.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="13"/>
                  <measurement group_id="O6" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs.</title>
        <description>Unsolicited AEs were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 84 days following first dose or 63 days following second dose of vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited AEs.</title>
            <description>Unsolicited AEs were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period (up to Day 507).</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
            <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Case Descriptions for Subjects Experiencing Reverse Transcription-polymerase Chain Reaction (RT-PCR) and Culture-confirmed Influenza.</title>
        <time_frame>During the entire study period (up to Day 507).</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>09/2012</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination. Missing values will be added once they become available.</description>
        <time_frame>Up to Day 234</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
            <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. Related = symptom assed by the investigator as causally related to the study vaccination. Missing values will be added once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</title>
        <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within Days 0-233</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).</title>
            <description>MAEs refer to events that required medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any MAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related MAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</title>
        <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within Days 0-233</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).</title>
            <description>pIMDs are a subset of adverse events (AEs) that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related = symptom assed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any pIMDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related pIMDs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="66"/>
                  <measurement group_id="O6" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="35"/>
                  <measurement group_id="O6" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="66"/>
                  <measurement group_id="O6" value="64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited General Symptoms.</title>
            <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Flulaval vaccine or placebo dose. Missing values will be added once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="18"/>
                  <measurement group_id="O6" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="19"/>
                  <measurement group_id="O6" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint pain at other location</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="13"/>
                  <measurement group_id="O6" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="20"/>
                  <measurement group_id="O6" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="8"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sweating</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="9"/>
                  <measurement group_id="O6" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Missing values will be added once they become available.</description>
        <time_frame>During the 7-day (Days 0-6) follow-up period after vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited General Symptoms.</title>
            <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature (= axillary temperature equal to or above 38.0 degrees Celsius (°C)) and were collected after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine. Missing values will be added once they become available.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint pain at other location</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
        <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
        <time_frame>On Days 0, 21, 122 and 164</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
            <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Baseline Within-Day 0 Within (N=33;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-Day 21 Unknown (N=32;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-Day 21 Within (N=32;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-Day 122 Unknown (N=29;33;30;28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-Day 122 Within (N=29;33;30;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-Day 164 Within (N=25;33;26;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-Day 0 Within (N=0;0;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 0 Below (N=32;32;30;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 0 Within (N=32;32;30;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 0 Above (N=32;32;30;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 0 Within (N=1;2;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 0 Above (N=1;2;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-Day 21 Within (N=0;0;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 21 Unkown (N=31;32;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 21 Below (N=31;32;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 21 Within (N=31;32;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 21 Above (N=31;32;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 21 Within (N=1;2;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-Day 122 Within (N=0;0;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 122 Unknown (N28;31;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 122 Below (N28;31;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 122 Within (N28;31;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 122 Above (N28;31;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 122 Within (N=1;2;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 122 Above (N=1;2;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-Day 164 Within (N=0;0;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 164 Below (N24;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 164 Within (N24;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-Day 164 Above (N24;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-Day 164 Within (N=1;2;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 0 Below (N=33;33;32;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 0 Within (N=33;33;32;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 0 Within (N=0;1;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 21 Unknown (N=32;33;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 21 Below (N=32;33;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 21 Within (N=32;33;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 21 Within (N=0;1;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 122 Unknown (N=29;32;29;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 122 Below (N=29;32;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 122 Within (N=29;32;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 122 Above (N=29;32;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 122 Within (N=0;1;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 122 Above (N=0;1;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 164 Below (N=25;32;26;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 164 Within (N=25;32;26;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-Day 164 Above (N=25;32;26;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 164 Within (N=0;1;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-Day 164 Above (N=0;1;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 0 Below (N=33;34;32;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 0 Within (N=33;34;32;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Above-Day 0 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 21 Unknown (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 21 Below (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 21 Within (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Above-Day 21 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 122 Unknown (N=29;33;29;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 122 Below (N=29;33;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 122 Within (N=29;33;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Above-Day 122 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 164 Below (N=25;33;26;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-Day 164 Within (N=25;33;26;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Above-Day 164 Within (N=0;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 0 Below (N=33;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 0 Within (N=33;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 0 Above (N=33;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 21 Unknown (N=32;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 21 Within (N=32;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 21 Above (N=32;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 122 Unknown (N=29;33;30;28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 122 Within (N=29;33;30;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-Day 164 Within (N=25;33;26;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 0 Below (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 0 Within (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 0 Below (N=30;30;29;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 0 Within (N=30;30;29;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 21 Below (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 21 Within (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 21 Unknown (N=29;30;27;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 21 Below (N=29;30;27;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 21 Within (N=29;30;27;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 122 Unknown (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 122 Below (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 122 Within (N=3;4;4;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 122 Unknown (N=26;29;26;21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 122 Below (N=26;29;26;21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 122 Within (N=26;29;26;21)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day 164 Below (N=3;4;3;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-Day164 Within (N=3;4;3;7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 164 Below (N=22;29;23;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-Day 164 Within (N=22;29;23;20)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 0 Below (N=33;33;29;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 0 Within (N=33;33;29;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 0 Above (N=33;33;29;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-Day 0 Within (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-Day 0 Above (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-Day 21 Within (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 21 Unknown (N=32;33;28;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 21 Below (N=32;33;28;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 21 Within (N=32;33;28;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 21 Above (N=32;33;28;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-Day 21 Within (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-Day 122 Unknown (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-Day 122 Within (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 122 Unknown (N=29;32;27;28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 122 Below (N=29;32;27;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 122 Within (N=29;32;27;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 122 Above (N=29;32;27;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-Day 122 Within (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-Day 164 Within (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 164 Below (N=25;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 164 Within (N=25;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-Day 164 Above (N=25;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-Day 164 Within (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 0 Below (N=32;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 0 Within (N=32;34;33;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Above-Day 0 Above (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 21 Within (N=31;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 21 Within (N=31;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 122 Unknown (N=28;33;29;28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 122 Below (N=28;33;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 122 Within (N=28;33;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Above-Day 122 Above (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 164 Unknown (N=24;33;26;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 164 Below (N=24;33;26;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 164 Within (N=24;33;26;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-Day 164 Above (N=24;33;26;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Above-Day 164 Above (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 0 Below (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 0 Within (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 0 Below (N=32;33;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 0 Within (N=32;33;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 0 Within (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 0 Above (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 21 Below (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 21 Within (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 21 Unknown (N=31;33;29;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 21 Below (N=31;33;29;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 21 Within (N=31;33;29;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 0 Within (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 122 Unknown (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 122 Below (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 122 Within (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 122 Unknown (N=28;32;28;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 122 Below (N=28;32;28;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 122 Within (N=28;32;28;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 122 Within (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 122 Above (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 164 Below (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-Day 164 Within (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 164 Below (N=24;32;24;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-Day 164 Within (N=24;32;24;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 164 Within (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-Day 164 Above (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 0 Below (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 0 Below (N=31;33;31;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 0 Within (N=31;33;31;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 0 Within (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 0 Above (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 21 Below (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 21 Within (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 21 Unknown (N=30;33;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 21 Below (N=30;33;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 21 Within (N=30;33;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="27"/>
                  <measurement group_id="O4" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 21 Above (N=30;33;29;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 21 Within (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 21 Above (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 122 Below (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 122 Within (N=0;0;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 122 Unknown (N=27;32;28;28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 122 Below (N=27;32;28;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 122 Within (N=27;32;28;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 122 Above (N=27;32;28;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 122 Within (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 122 Above (N=2;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-Day 164 Below (N=0;0;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 164 Below (N=24;32;35;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 164 Within (N=24;32;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-Day 164 Above (N=24;32;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 164 Within (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-Day 164 Above (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
        <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatise (AP), creatinine (CREA), blood urea nitrogen (BUN) and bilirubin (BIL) (total (T) and direct (D)).
For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
        <time_frame>On Days 0, 21, 122 and 164</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Total Vaccinated cohort included all vaccinated subjects for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
            <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatise (AP), creatinine (CREA), blood urea nitrogen (BUN) and bilirubin (BIL) (total (T) and direct (D)).
For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALAT Baseline Within-Day 0 Within (N=31,34,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 0 Above (N=31,34,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Above-Day 0 Above (N=2,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 21 Unknown (N=30,34,31,32</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 21 Within (N=30,34,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Above-Day 21 Above (N=2,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 122 Within (N=27,33,30,28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 122 Above (N=27,33,30,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Above-Day 122 Above (N=2,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 164 Within (N=24,33,26,27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-Day 164 Above (N=24,33,26,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Above-Day 164 Above (N=1,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-Day 0 Within (N=32,33,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-Day 0 Within (N=1,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-Day 0 Above (N=1,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-Day 21 Unknown (N=31,33,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-Day 21 Within (N=31,33,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-Day 21 Above (N=1,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-Day 122 Within (N=28,32,30,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-Day 122 Above (N=1,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-Day 164 Within (N=24,32,26,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-Day 164 Above (N=1,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Unknown-Day 0 Within (N=0,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 0 Within (N=33,33,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="32"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 0 Above (N=33,33,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Unknown-Day 21 Within (N=0,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 21 Unknown (N=32,33,31,32</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 21 Within (N=32,33,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 21 Above (N=32,33,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Unknown-Day 122 Within (N=0,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 122 Within (N=29,32,30,28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 122 Above (N=29,32,30,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Unknown-Day 164 Within (N=0,1,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 164 Within (N=25,32,26,27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-Day 164 Above (N=25,32,26,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 0 Within (N=32,34,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 0 Above (N=32,34,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Above-Day 0 Within (N=1,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 21 Unknown (N=31,34,31,32</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 21 Within (N=31,34,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 21 Above (N=31,34,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Above-Day 21 Within (N=1,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 122 Within (N=28,33,30,28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 122 Above (N=28,33,30,28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Above-Day 122 Within (N=1,0,0,0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 164 Within (N=25,33,26,27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-Day 164 Above (N=25,33,26,27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-Day 0 Within (N=33,34,33,33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-Day 21 Unknown (N=32,34,31,32</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-Day 21 Within (N=32,34,31,32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-Day 122 Within (N=29,33,30,28</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-Day 164 Within (N=25,33,26,27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 0 Below (N=2;1;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 0 Within (N=2;1;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 0 Below (N=31;33;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 0 Within (N=31;33;29;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 21 Below (N=2;1;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 21 Within (N=2;1;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 21 Unknown (N=30;33;27;27</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 21 Below (N=30;33;27;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 21 Within (N=30;33;27;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 21 Above (N=30;33;27;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 122 Below (N=2;0;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 122 Within (N=2;0;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 122 Below (N=27;33;26;23)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 122 Within (N=27;33;26;23</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 164 Below (N=2;0;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-Day 164 Within (N=2;0;4;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 164 Below (N=23;33;22;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-Day 164 Within (N=23;33;22;22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 0 Below (N=0;0;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 0 Within (N=0;0;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 0 Below (N=33;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 0 Within (N=33;34;31;32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="31"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 21 Below (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 21 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 21 Unknown (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 21 Below (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 21 Within (N=32;34;30;31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="34"/>
                  <measurement group_id="O3" value="30"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 122 Below (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 122 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 122 Within (N=29;33;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="29"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 122 Above (N=29;33;29;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-Day 164 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 164 Below (N=25;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 164 Within (N=25;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-Day 164 Above (N=25;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
        <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
        <time_frame>At Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
            <description>Laboratory parameters assessed were white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS), basophils (BAS), red blood cells (RBC), hemoglobin (Hgb), hematocrit (Hct) and platelets (PLA). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BAS Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-D304 Unknown (N=24;31;21;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS Baseline Within-D304 Within (N=24;31;21;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Unknown-D304 Below (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-D304 Below (N=2;4;4;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Below-D304 Within (N=2;4;4;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-D304 Unknown (N=21;26;17;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-D304 Below (N=21;26;17;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Within-D304 Within (N=21;26;17;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-D304 Within (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS Baseline Above-D304 Above (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Unknown-D304 Below (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Below-D304 Below (N=1;2;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Below-D304 Within (N=1;2;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-D304 Unknown (N=23;29;19;24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-D304 Below (N=23;29;19;24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-D304 Within (N=23;29;19;24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Within-D304 Above (N=23;29;19;24)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-D304 Within (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hct Baseline Above-D304 Above (N=0;0;1;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Unknown-D304 Below (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Below-D304 Below (N=3;3;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Below-D304 Within (N=3;3;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-D304 Unknown (N=21;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-D304 Below (N=21;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hgb Baseline Within-D304 Within (N=21;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-D304 Unknown (N=24;31;21;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-D304 Within (N=24;31;21;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM Baseline Within-D304 Above (N=24;31;21;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-D304 Unknown (N=3;5;5;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-D304 Below (N=3;5;5;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Below-D304 Within (N=3;5;5;10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-D304 Unknown (N=21;26;16;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-D304 Below (N=21;26;16;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON Baseline Within-D304 Within (N=21;26;16;16)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-D304 Below (N=2;1;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Below-D304 Within (N=2;1;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-D304 Unknown (N=22;29;21;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-D304 Below (N=22;29;21;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-D304 Within (N=22;29;21;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Within-D304 Above (N=22;29;21;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU Baseline Above-D304 Within (N=0;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Unknown-D304 Within (N=1;2;1;4)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Below-D304 Unknown (N=0;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-D304 Unknown (N=23;30;21;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-D304 Below (N=23;30;21;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-D304 Within (N=23;30;21;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Within-D304 Above (N=23;30;21;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA Baseline Above-D304 Above (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Unknown-D304 Below (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-D304 Unknown (N=0;2;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-D304 Below (N=0;2;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Below-D304 Within (N=0;2;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-D304 Unknown (N=23;29;19;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-D304 Below (N=23;29;19;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-D304 Within (N=23;29;19;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Within-D304 Above (N=23;29;19;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC Baseline Above-D304 Above (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Unknown-D304 Unknown (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Unknown-D304 Within (N=1;1;2;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-D304 Below (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Below-D304 Within (N=0;1;2;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-D304 Unknown (N=23;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-D304 Below (N=23;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-D304 Within (N=23;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="24"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Within-D304 Above (N=23;28;19;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-D304 Within (N=1;2;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC Baseline Above-D304 Above (N=1;2;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
        <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), creatinine (CREA), blood urea nitrogen (BUN), and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
        <time_frame>At Day 304</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.</title>
            <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), creatinine (CREA), blood urea nitrogen (BUN), and bilirubin (BIL) (total (T) and direct (D)). For each parameter and for each status at baseline it was assessed whether the post-vaccination values of the parameter were above, below or within the range (unkown values are also indicated).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALAT Baseline Within-D304 Within (N=24;32;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Within-D304 Above (N=24;32;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALAT Baseline Above-D304 Within (N=1;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-D304 Within (N=24;30;22;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="21"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Within-D304 Above (N=24;30;22;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-D304 Within (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AP Baseline Above-D304 Above (N=1;1;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-D304 Within (N=24;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Within-D304 Above (N=24;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ASAT Baseline Above-D304 Within (N=1;0;0;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-D304 Within (N=25;31;22;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="29"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Within-D304 Above (N=25;31;22;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Above-D304 Within (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILT Baseline Above-D304 Above (N=0;1;1;0)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-D304 Within (N=25;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BILD Baseline Within-D304 Above (N=25;32;23;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-D304 Below (N=2;0;2;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Below-D304 Within (N=2;0;2;5)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-D304 Below (N=23;31;20;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA Baseline Within-D304 Within (N=23;31;20;22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Below-D304 Below (N=0;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Within-D304 Within (N=25;31;22;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BUN Baseline Above-D304 Within (N=0;0;0;1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
        <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;= 1:10 Flu A/CAL/7/09 H1N1 pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="22"/>
                  <measurement group_id="O6" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/CAL/7/09 H1N1 Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="30"/>
                  <measurement group_id="O6" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/CAL/7/09 H1N1 Day 17</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="39"/>
                  <measurement group_id="O6" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/CAL/7/09 H1N1 Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="36"/>
                  <measurement group_id="O6" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
        <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="12.5" lower_limit="8.6" upper_limit="18.2"/>
                  <measurement group_id="O6" value="13.9" lower_limit="9.6" upper_limit="20.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="14.8" lower_limit="10.2" upper_limit="21.5"/>
                  <measurement group_id="O6" value="13.8" lower_limit="9.6" upper_limit="20.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="19.9" lower_limit="13.7" upper_limit="28.7"/>
                  <measurement group_id="O6" value="13.8" lower_limit="9.6" upper_limit="19.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="17.8" lower_limit="12.4" upper_limit="25.6"/>
                  <measurement group_id="O6" value="13.3" lower_limit="9.3" upper_limit="19.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 122 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.1" lower_limit="8.9" upper_limit="29.3"/>
                  <measurement group_id="O2" value="12.5" lower_limit="7.7" upper_limit="20.1"/>
                  <measurement group_id="O3" value="13.9" lower_limit="8.1" upper_limit="24.0"/>
                  <measurement group_id="O4" value="12.9" lower_limit="8.1" upper_limit="20.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 129 (N=21;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66.7" lower_limit="35.7" upper_limit="124.6"/>
                  <measurement group_id="O2" value="54.6" lower_limit="28.7" upper_limit="103.9"/>
                  <measurement group_id="O3" value="83.3" lower_limit="44.2" upper_limit="157.3"/>
                  <measurement group_id="O4" value="70.3" lower_limit="38.8" upper_limit="127.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 136 (N=21;33;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="491.6" lower_limit="319.3" upper_limit="756.9"/>
                  <measurement group_id="O2" value="303.7" lower_limit="191.7" upper_limit="481.0"/>
                  <measurement group_id="O3" value="602.5" lower_limit="434.1" upper_limit="836.4"/>
                  <measurement group_id="O4" value="385.6" lower_limit="242.9" upper_limit="612.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 143 (N=21;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="390.1" lower_limit="266.3" upper_limit="571.5"/>
                  <measurement group_id="O2" value="256.6" lower_limit="164.9" upper_limit="399.3"/>
                  <measurement group_id="O3" value="557.3" lower_limit="426.5" upper_limit="728.3"/>
                  <measurement group_id="O4" value="365.6" lower_limit="241.3" upper_limit="553.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 150 (N=19;31;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="452.8" lower_limit="305.6" upper_limit="670.9"/>
                  <measurement group_id="O2" value="292.7" lower_limit="198.0" upper_limit="432.7"/>
                  <measurement group_id="O3" value="565.0" lower_limit="423.3" upper_limit="754.1"/>
                  <measurement group_id="O4" value="333.3" lower_limit="220.8" upper_limit="503.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 157 (N=20;32;24;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="651.3" lower_limit="487.1" upper_limit="870.8"/>
                  <measurement group_id="O2" value="303.2" lower_limit="215.1" upper_limit="427.4"/>
                  <measurement group_id="O3" value="818.1" lower_limit="634.9" upper_limit="1054.0"/>
                  <measurement group_id="O4" value="338.2" lower_limit="230.7" upper_limit="495.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/CAL/7/09 H1N1 Day 164 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="650.7" lower_limit="485.5" upper_limit="872.1"/>
                  <measurement group_id="O2" value="259.4" lower_limit="186.4" upper_limit="361.0"/>
                  <measurement group_id="O3" value="799.0" lower_limit="630.5" upper_limit="1012.4"/>
                  <measurement group_id="O4" value="332.7" lower_limit="222.0" upper_limit="498.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
        <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.
Seropositivity rates of H1N1 HI antibody titers in terms of humoral immune response were also calculated for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;= 1:10 Flu A/BRI/59/07 H1N1 Pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="48"/>
                  <measurement group_id="O6" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/BRI/59/07 H1N1 Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/BRI/59/07 H1N1 Day 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 Flu A/BRI/59/07 H1N1 Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
        <time_frame>Before vaccination and at Days 7, 14 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O5">
            <title>Flulaval Group</title>
            <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Group</title>
            <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                  <measurement group_id="O5" value="54"/>
                  <measurement group_id="O6" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs). GMTs of H1N1 HI antibody titers in terms of humoral immune response were also calculated with 95% CI, for both pooled Flulaval (Flulaval/Arepanrix + Flulaval/Unadjuvanted Arepanrix Groups) and Placebo (Placebo/Arepanrix + Placebo/Unadjuvanted Arepanrix Groups) treatment groups at Days 0, 7, 14 and 21 up to the administration of the first dose of Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 pre-vaccination</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="23.3" lower_limit="17.7" upper_limit="30.5"/>
                  <measurement group_id="O6" value="18.7" lower_limit="14.6" upper_limit="23.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 Day 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="65.5" lower_limit="47.4" upper_limit="90.6"/>
                  <measurement group_id="O6" value="18.3" lower_limit="14.4" upper_limit="23.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 Day 14</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="213.6" lower_limit="153.0" upper_limit="298.2"/>
                  <measurement group_id="O6" value="18.4" lower_limit="14.2" upper_limit="23.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Flu A/BRI/59/07 H1N1 Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                  <measurement group_id="O3"/>
                  <measurement group_id="O4"/>
                  <measurement group_id="O5" value="200.3" lower_limit="146.0" upper_limit="274.8"/>
                  <measurement group_id="O6" value="18.8" lower_limit="14.6" upper_limit="24.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
        <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>A seropositive subject was a subject whose HI antibody titer was greater than or equal to the assay cut-off value of 1:10.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="22"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 1:10 A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>At Days 122, 129, 136, 143, 150, 157 and 164.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The According-To-Protocol cohort for immunogenicity at Day 164 included subjects who had not received a vaccine not specified in the protocol during the primary vaccination course, for whom 3 doses were administered and assay results were available for antibodies against H1N1 antigen at day 21 after the second H1N1 vaccine dose (Day 164).</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Unadjuvanted Arepanrix Group</title>
            <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="25"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.</title>
            <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 122 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135.6" lower_limit="87.5" upper_limit="209.9"/>
                  <measurement group_id="O2" value="125.7" lower_limit="85.3" upper_limit="185.0"/>
                  <measurement group_id="O3" value="18.4" lower_limit="13.5" upper_limit="25.0"/>
                  <measurement group_id="O4" value="18.0" lower_limit="12.2" upper_limit="26.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 129 (N=21;31;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140.4" lower_limit="86.9" upper_limit="226.7"/>
                  <measurement group_id="O2" value="126.5" lower_limit="85.6" upper_limit="186.9"/>
                  <measurement group_id="O3" value="27.0" lower_limit="20.6" upper_limit="35.4"/>
                  <measurement group_id="O4" value="24.4" lower_limit="17.9" upper_limit="33.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 136 (N=21;33;23;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144.9" lower_limit="90.0" upper_limit="233.4"/>
                  <measurement group_id="O2" value="144.1" lower_limit="98.0" upper_limit="211.9"/>
                  <measurement group_id="O3" value="44.4" lower_limit="32.2" upper_limit="61.2"/>
                  <measurement group_id="O4" value="38.9" lower_limit="26.5" upper_limit="57.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 143 (N=21;33;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140.3" lower_limit="91.5" upper_limit="215.1"/>
                  <measurement group_id="O2" value="129.6" lower_limit="88.9" upper_limit="189.1"/>
                  <measurement group_id="O3" value="38.8" lower_limit="29.1" upper_limit="51.7"/>
                  <measurement group_id="O4" value="35.4" lower_limit="23.9" upper_limit="52.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 150 (N=19;31;25;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="146.1" lower_limit="91.2" upper_limit="234.2"/>
                  <measurement group_id="O2" value="138.2" lower_limit="93.5" upper_limit="204.1"/>
                  <measurement group_id="O3" value="44.0" lower_limit="33.0" upper_limit="58.8"/>
                  <measurement group_id="O4" value="34.5" lower_limit="24.5" upper_limit="48.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 157 (N=20;32;24;25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144.2" lower_limit="93.4" upper_limit="222.7"/>
                  <measurement group_id="O2" value="131.5" lower_limit="89.1" upper_limit="194.1"/>
                  <measurement group_id="O3" value="49.6" lower_limit="35.9" upper_limit="68.6"/>
                  <measurement group_id="O4" value="33.8" lower_limit="24.1" upper_limit="47.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT A/BRI/59/07 H1N1 Day 164 (N=21;33;25;27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144.9" lower_limit="97.2" upper_limit="216.1"/>
                  <measurement group_id="O2" value="123.1" lower_limit="87.1" upper_limit="174.0"/>
                  <measurement group_id="O3" value="49.2" lower_limit="33.9" upper_limit="71.2"/>
                  <measurement group_id="O4" value="35.2" lower_limit="25.7" upper_limit="48.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: During the entire study period (up to Day 507). Solicited AEs: During a 7-day follow-up period after administration of vaccine.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flulaval/Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="E2">
          <title>Flulaval/Unadjuvanted Arepanrix Group</title>
          <description>subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.</description>
        </group>
        <group group_id="E5">
          <title>Flulaval Group</title>
          <description>subjects from the Flulaval/Arepanrix Group and the Flulaval/Unadjuvanted Arepanrix Group were pooled.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Group</title>
          <description>subjects from the Placebo/Arepanrix Group and the Placebo/Unadjuvanted Arepanrix Group were pooled.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Solicited local symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Flulaval or Placebo dose.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Solicited local symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Solicited local symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>Solicited general symptom reported during the 7-day (Days 0-6) after the administration of the Arepanrix or the unadjuvanted formulation of Arepanrix vaccine.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
